Revenue

6 Months Ended

Mar. 31, 2022

Revenue From Contract With Customer [Abstract]

Revenue

2. Revenue

The following table presents the Company’s revenues disaggregated by product classification and by reportable segment.

	Three Months Ended March 31,				Six Months Ended March 31,
(In thousands)	2022		2021		2022		2021
Medical Device
Product sales	$	6,441	$	5,410	$	13,229	$	9,971
Royalties		8,358		7,474		15,244		15,383
License fees		1,486		12,578		2,699		14,003
Research, development and other		2,168		2,445		4,189		4,746
Medical Device Revenue		18,453		27,907		35,361		44,103
In Vitro Diagnostics
Product sales		7,523		6,373		13,079		11,914
Research, development and other		130		715		669		1,275
In Vitro Diagnostics Revenue		7,653		7,088		13,748		13,189
Total Revenue	$	26,106	$	34,995	$	49,109	$	57,292

Contract assets totaled $7.2 million and $7.1 million as of March 31, 2022 and September 30, 2021, respectively. Fluctuations in the balance of contract assets result primarily from changes in sales-based and minimum royalties earned, but not collected, at each balance sheet date due to payment timing and contractual changes in the normal course of business. For discussion of contract liability (deferred revenue) balances and remaining performance obligations, see Note 3 Collaborative Arrangement.